- Home
- MIRM
as 01-17-2025 4:00pm EST
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | FOSTER CITY |
| Market Cap: | 2.1B | IPO Year: | 2019 |
| Target Price: | $57.00 | AVG Volume (30 days): | 450.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.12 | EPS Growth: | N/A |
| 52 Week Low/High: | $23.14 - $48.89 | Next Earning Date: | 02-26-2025 |
| Revenue: | $307,028,000 | Revenue Growth: | 112.14% |
| Revenue Growth (this year): | 82.14% | Revenue Growth (next year): | 26.18% |
Stock Insider Trading Activity of Mirum Pharmaceuticals Inc. (MIRM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Radovich Peter | MIRM | PRESIDENT AND COO | Jan 7 '25 | Sell | $42.82 | 1,998 | $85,544.97 | 27,015 | |
| Peetz Christopher | MIRM | CHIEF EXECUTIVE OFFICER | Jan 7 '25 | Sell | $42.82 | 7,489 | $320,643.78 | 119,359 | |
| Howe Jolanda | MIRM | SVP, GLOBAL CONTROLLER | Jan 6 '25 | Sell | $42.82 | 750 | $32,111.48 | 2,926 | |
| Howe Jolanda | MIRM | SVP, GLOBAL CONTROLLER | Nov 14 '24 | Sell | $47.10 | 2,500 | $117,752.00 | 2,926 |
Latest Mirum Pharmaceuticals Inc. News
MIRM Breaking Stock News: Dive into MIRM Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
MIRM Shares Rise 12% in a Week on Robust Preliminary 2024 Results
Simply Wall St.
4 days ago
Exploring Three High Growth Tech Stocks in the United States
Zacks
5 days ago
Axsome (AXSM) Moves 11.5% Higher: Will This Strength Last?
Zacks
5 days ago
Mirum Pharmaceuticals (MIRM) Is a Great Choice for 'Trend' Investors, Here's Why
Business Wire
6 days ago
Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates
Business Wire
8 days ago
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
10 days ago
Mirum Pharmaceuticals Insider Sold Shares Worth $320,644, According to a Recent SEC Filing
Business Wire
12 days ago
Mirum Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Compare MIRM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MIRM Mirum Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.